biostudies-literatureRedline SNHLBI NIH HHS1951-1960https://www.ebi.ac.uk/biostudies/studies/S-EPMC12700247biostudies-literatureUnknown22(12)<b>Rationale:</b> There are insufficient data to inform the management of central sleep apnea (CSA) in patients with heart failure with reduced ejection fraction (HFrEF). Nocturnal oxygen therapy (NOT) has been postulated to benefit CSA patients with HFrEF but has not been rigorously studied. <b>Objectives:</b> To compare NOT with sham NOT (control) in heart failure (HF) patients receiving guideline-based HF therapy on the composite outcome of first occurrence of either mortality due to any cause, a lifesaving cardiovascular intervention, or an unplanned hospitalization for worsening HF, together with other secondary outcomes. <b>Methods:</b> A multisite, double-blind, sham-controlled randomized clinical trial was conducted from September 2019 to December 2021, when the study was terminateAnnals of the American Thoracic SocietyNocturnal Oxygen Therapy for Central Sleep Apnea in Patients with Heart Failure: A Multisite, Double-Blind, Sham-controlled Randomized Clinical Trial (LOFT-HF).PMC12700247UG3 HL140144UG3HL140144U24 HL140412U24HL140412Yaggi HKAuckley DAbraham WTShah NJohnson MRJavaheri SKhayat RZee PCTeodorescu MMajid RChi LParthasarathy SAzarbarzin AKao AWang RDunlap MWolfe LSands SAPatel SRMehra RHsich EStewart GVader JGottlieb DJLewis EFLi DPolonsky TMokhlesi BRedline SBadr MSFang JCBrown LKRueschman MAlex RfalseNocturnal Oxygen Therapy for Central Sleep Apnea in Patients with Heart Failure: A Multisite, Double-Blind, Sham-controlled Randomized Clinical Trial (LOFT-HF).<b>Rationale:</b> There are insufficient data to inform the management of central sleep apnea (CSA) in patients with heart failure with reduced ejection fraction (HFrEF). Nocturnal oxygen therapy (NOT) has been postulated to benefit CSA patients with HFrEF but has not been rigorously studied. <b>Objectives:</b> To compare NOT with sham NOT (control) in heart failure (HF) patients receiving guideline-based HF therapy on the composite outcome of first occurrence of either mortality due to any cause, a lifesaving cardiovascular intervention, or an unplanned hospitalization for worsening HF, together with other secondary outcomes. <b>Methods:</b> A multisite, double-blind, sham-controlled randomized clinical trial was conducted from September 2019 to December 2021, when the study was terminate2025-01-01T00:00:00Z2025 Dec2026-06-06T02:16:35.772Z2026-05-24T03:12:18.693ZS-EPMC127002474092965010.1513/AnnalsATS.202504-409OC